Eculizumab 300 Mg Injection Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 300mg/30ml
Reference Brands: Bkemv (USA), Soliris (EU/LATAM)
Category:
Orphan Drugs
Eculizumab injection is used to treat a type of blood disease called paroxysmal nocturnal hemoglobinuria (PNH). This medicine helps reduce red blood cell destruction or breakdown (hemolysis) in patients with PNH.
Eculizumab 300 mg Injection is available in Injection
and strengths such as 300mg/30ml.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Eculizumab 300 mg Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Eculizumab 300 mg Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Eculizumab-aeeb is a highly targeted biologic medicine used in the treatment of rare complement-mediated disorders, particularly paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare genetic condition characterized by intermittent destruction of red blood cells due to uncontrolled activation of the complement system. The underlying cause of PNH is a deficiency of CD59, a natural complement inhibitor that normally protects red blood cells from the membrane attack complex (MAC). Without this protective mechanism, red blood cells are vulnerable to complement-mediated lysis, leading to anemia, fatigue, and other complications.
Eculizumab-aeeb works by specifically inhibiting complement protein C5, effectively preventing the formation of the MAC and reducing the destruction of red blood cells. This targeted mechanism helps control hemolysis, improves patient quality of life, and reduces the risk of complications associated with PNH. As a recombinant monoclonal antibody, Eculizumab-aeeb is produced using advanced biotechnology and is available in regulated markets across the United States, Europe, and other international regions. Its clinical effectiveness has made it a cornerstone therapy for patients living with this rare and life-impacting condition.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing